Key facts
- Frontier Bio’s last known valuation is $2.7M (Sep 2019).
- It has raised $2.9M; the latest was Equity Crowdfunding ($1.6M) in Mar 2026.
- Notable investors include US National Science Foundation, StartX (US), Alchemist Accelerator, Berkeley SkyDeck, MicroVentures — 28 tracked in total.
- 1 investment vehicle was formed to buy Frontier Bio shares in the last 12 months, per SEC Form D filings.
- Status: Privately Held (backing).
- ·The complete investor list — 28 names
- ·Watchlist + deal alerts for Frontier Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Frontier Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Secondary demand: investment vehicles
from SEC Form D filingsIn the last 12 months, 1 investment vehicle were formed to buy Frontier Bio shares. Most recent filing Jan 2026. Vehicles like these are how secondary buyers pool demand for a name; a rising count is a demand signal.
About Frontier Bio
Developer of engineered tissue technologies designed to create human-compatible vascular grafts and tissue models. The company's platform offers bioresorbable scaffolds, stem cell-based graft development, and lab-grown tissue models, enabling healthcare providers and research organizations to treat vascular conditions and conduct preclinical testing.
- Sector
- Healthcare
- HQ
- Hayward, CA, United States
- Founded
- 2018
- Employees
- 5
- Website
- frontierbio.com/
- Ownership
- Privately Held (backing)
Frontier Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Frontier Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Frontier Bio in its N-PORT filings yet. We sweep new filings monthly.